Inovio Pharma (INO)
$21.45 1.72 (8.72%)
19:59 EDT INO Stock Quote Delayed 30 Minutes
Previous Close $21.45
Market Cap 1.95B
PE Ratio -18.82
Volume (Avg. Vol.) 52.61M
Day's Range 19.90 - 22.48
52-Week Range 1.92 - 33.79
Dividend & Yield N/A (N/A)
INO Stock Predictions, Articles, and Inovio Pharma News
- From InvestorPlace
- From the Web
These high-risk stocks are ignoring everything from valuation to coronavirus risks, and are instead pushing to new highs.
Micron, the gold ETF, Barrick Gold, Inovio and Uber were our top stock trades for Wednesday. That said, let's look at the charts now.
Young investors are beating Wall Street pros in 2020, and these are the hot stocks they are using to pull off this unthinkable feat.
Covid-19 vaccine stocks are on fire, but many of them appear to be out over their skis, including the group's hottest name, NVAX stock.
For new investors, stocks under $10 offer both learning opportunities and huge upside potential. Here are 10 names to buy cheap.
Covid-19 vaccine stocks are red-hot right now thanks to the emergence of a second wave, but I'd be careful chasing this rally in INO stock.
McCormick, Sorrento, Square and Inovio were our top stock trades from Thursday. So, let's look at the charts to see what's going on now.
Inovio stock has already been a strong performer in 2020, but news of a DOD contract for COVID-19 vaccine applicators has INO stock soaring.
With pandemic fears shuttering many economies, most investments have cratered. However, a small group of coronavirus stocks may offer significant upside potential.
Inovio Pharmaceuticals (INO) is in the news Tuesday after a contract with the U.S. Department of Defense sent INO stock soaring higher.
Inovio Pharma's next clinical results will be a binary event for INO Stock. It will rise or fall based on its Phase 1 results due out by the end of June.
INO stock has been on a tear in recent months, but the shares may not necessarily make any new highs. Consider taking your profits now.
INO stock is up over 300% in 2020. But investors are going all in on the company's Covid-19 vaccine candidate, and that's still a gamble.
Inovio is speeding toward a vaccine for the coronavirus and has plans to make 1 million doses by the end of the year to boost INO stock.
Inovio has an attractive technical profile, but not very good fundamentals. Let's look at what bulls can utilize in INO stock.
INO stock is still attracting strong buying interest but investors may want to wait for the dust to settle first before adding shares.
Inovio's COVID-19 vaccine faces huge hurdles. INO stock will tread water until its manufacturing and financing issues are overcome.
The government probably won't help Inovio with its coronavirus vaccine and the company has other problems besides. Investors should sell INO stock.
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
Navellier RatingsPowered by Portfolio Grader